Efficacy and safety of nemolizumab in paediatric atopic dermatitis: A 24-week real-world case series - PubMed
6 hours ago
- #paediatric
- #atopic dermatitis
- #nemolizumab
- Study evaluates efficacy and safety of nemolizumab in pediatric atopic dermatitis over 24 weeks.
- Nemolizumab targets interleukin-31, addressing pruritus in atopic dermatitis.
- References include real-world studies and clinical trials supporting nemolizumab's use.
- Phase III trial shows efficacy in children aged 6-12 with moderate-to-severe pruritus.
- Long-term safety and efficacy data up to 2 years available from extension studies.